Factors Linked to AI Literacy in University Students
Launched by NAGIHAN ACET · Nov 13, 2024
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well university students understand artificial intelligence (AI) and what factors may influence their knowledge. Researchers want to find out if things like academic performance, reading habits, smartphone use, and internet habits impact how well students can understand and evaluate AI technologies. As AI becomes a bigger part of our lives, being knowledgeable about it is important. The study will involve students aged 18 to 35 from the Physiotherapy and Rehabilitation Department at Atılım University.
To take part in the study, participants need to be between 18 and 35 years old and willing to learn more about the study before deciding to join. Those who don’t fill out the questionnaires completely, are unable to read, or can’t cooperate will not be included. Participants can expect to answer questions that will help researchers measure their AI literacy and explore how it relates to their academic and personal habits. The findings may help improve teaching methods for understanding AI in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being between 18-35 years of age.
- • Willingness to participate after receiving detailed information about the study's purpose and methodology.
- Exclusion Criteria:
- • Missing responses in questionnaires.
- • Illiteracy.
- • Inability to cooperate.
About Nagihan Acet
Nagihan Acet is a pioneering clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative studies. With a robust portfolio of clinical trials spanning various therapeutic areas, Nagihan Acet emphasizes rigorous scientific methodology and patient-centric approaches. The organization is committed to fostering collaboration with healthcare professionals, regulatory bodies, and research institutions to ensure the highest standards of safety, efficacy, and ethical conduct in all trial phases. By leveraging cutting-edge technologies and data analytics, Nagihan Acet aims to expedite the development of novel therapies and contribute to the global healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported